|Bid||47.40 x 800|
|Ask||47.45 x 900|
|Day's Range||46.80 - 47.60|
|52 Week Range||26.95 - 47.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.69|
Short interest is low for PCRX with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 13.
Pacira Pharmaceuticals, Inc. (PCRX) today reported that it will present at the 2018 Wedbush Pacgrow Healthcare Conference at 9:45 AM ET on Tuesday, August 14, 2018. Pacira Pharmaceuticals, Inc. (PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.
The Parsippany, New Jersey-based company said it had net income of 6 cents per share. Earnings, adjusted for one-time gains and costs, were 24 cents per share. The results surpassed Wall Street expectations. ...
Short interest is low for PCRX with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 13. Over the last one-month, outflows of investor capital in ETFs holding PCRX totaled $125 million.
--EXPAREL ® net product sales of $80.4 million up 15% over prior year second quarter---- Full-year EXPAREL net product sales guidance increased to $320 to $325 million---- Conference Call Today at 8:30 ...
We expect Zoetis (ZTS) to throw more light on its Abaxis acquisition plans and other pipeline updates during second-quarter 2018 earnings call.
Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Drugs - Generic stocks: The Medicines Co. (NASDAQ: MDCO), Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and SCYNEXIS Inc. (NASDAQ: SCYX).
Pacira Pharmaceuticals, Inc. (PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Thursday, August 2, 2018. International callers may dial 1-720-545-0035 and use the same passcode. Pacira Pharmaceuticals, Inc. (PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients.
Short interest is low for PCRX with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 13. Over the last one-month, outflows of investor capital in ETFs holding PCRX totaled $1.40 billion.
Pacira (PCRX) announces robust preliminary results for Exparel sales in second quarter on the back of increasing adoption for pain management in surgical procedures.
Pacira Pharmaceuticals, Inc. (PCRX) today reported preliminary EXPAREL® (bupivacaine liposome injectable suspension) net product sales of $80.4 million for the second quarter of 2018, a 15 percent increase over EXPAREL net product sales of $69.8 million reported in the second quarter of 2017. “We are excited to report another consecutive quarter of accelerating sales growth, representing the expanding adoption of EXPAREL as an integral component of multimodal, non-opioid pain management strategies in a variety of surgical procedures,” said Dave Stack, chairman and chief executive officer of Pacira. “Our Johnson & Johnson partnership is flourishing and we are continuing to see a high level of engagement and enthusiasm around the launch of EXPAREL as the first long-acting, single-dose nerve block for upper extremity surgeries with increasing demand from new and existing accounts.
Short interest is moderate for PCRX with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 8. The net inflows of $2.85 billion over the last one-month into ETFs that hold PCRX are not among the highest of the last year and have been slowing.
Ahead of today's trading session, WallStEquities.com assesses Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), SCYNEXIS Inc. (NASDAQ: SCYX), and The Medicines Co. (NASDAQ: MDCO). The biggest catalyst of the Generic Drugs industry is the significantly lower price of generics compared to branded drugs.
In this article I am going to calculate the intrinsic value of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by estimating the company’s future cash flows and discounting them to their present value.Read More...
Heron Therapeutics Inc. shares surged 30% Thursday, after the company announced positive developments for its treatment for postoperative pain that aims to reduce patient dependence on opioids. It then said that its HTX-011, which was the focus of the two studies, has won breakthrough therapy designation from the U.S. Food and Drug Administration. HTX-011 is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam and is intended for the management of postoperative pain.
Pacira Pharmaceuticals, Inc. (PCRX) and Nuance Biotech Co. Ltd (Nuance) today announced that they have entered into an agreement with Nuance, a China based specialty pharmaceutical company, to advance the development and commercialization of EXPAREL® (bupivacaine liposome injectable suspension) in China. EXPAREL is a non-opioid option for achieving long-lasting pain control after surgery via infiltration into the surgical site or administration as an interscalene brachial plexus nerve block.
NEW YORK, June 18, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Microchip ...
Pacira Pharmaceuticals, Inc. today announced further collaboration with Aetna, one of the nation’s leading diversified health care benefits companies. Aetna has updated its online provider directory, DocFind, to help members easily identify surgeons who are committed to offering opioid alternatives, including EXPAREL® (bupivacaine liposome injectable suspension), to manage postsurgical pain. This initiative builds off a national program launched by Pacira, Aetna, and the American Association of Oral and Maxillofacial Surgeons (AAOMS) in September 2017 aimed at reducing the number of opioid tablets prescribed to Aetna patients undergoing impacted wisdom tooth extractions through the use of EXPAREL.
MEDNAX, Inc. (MD), the national health solutions partner specializing in anesthesiology, neonatology, maternal-fetal medicine, other pediatric services, radiology and management services, is pleased to announce that it has partnered with Pacira Pharmaceuticals, Inc. (PCRX) to address the ongoing use of opioids during and after cesarean surgery by launching a national collaborative aimed at addressing the Quadruple Aim through the implementation of an Enhanced Recovery after Cesarean Surgery (ERACS™) program. The collaborative will be multi-disciplinary in nature, engaging the expertise of maternal-fetal medicine physicians, anesthesiologists, obstetricians and perioperative nurses to improve the patient experience as well as maternal and infant health, reduce the total cost of care and enhance provider satisfaction.
Pacira Pharmaceuticals (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.